The patient perspective has become even more important in the wake of the pandemic. Here’s how Clinica Dermacross is making it a priority.
This revised statement is based on expert opinion and should be interpreted in the context of local policies and emerging evidence.
PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes the first 1,652 cases.
The COVID-19 pandemic has been a significant concern, and vaccination has been crucial worldwide in its combat.
A research group led by Catherine Smith from St John’s Institute of Dermatology described humoral and cellular immunity.
It is not fully understood the impact that COVID-19 has on psoriasis patients.
The safety of treatment for immune-mediated diseases like psoriasis during the COVID-19 pandemic is a matter of concern. In an Israeli population-based nested case-control study using the Clalit Health Services database, 3,151 patients with psoriasis that tested positive for SARS-CoV-2 infection were identified.
Because of the growing body of evidence indicating sex differences in the clinical outcomes of coronavirus disease 2019 (COVID-19) infection, the IMPACT Research Team from Yale University investigated sex differences in viral loads, SARS-CoV-2-specific antibody titers, plasma cytokines, as well as blood cell phenotyping in COVID-19 patients.
An article recently published in the Journal of Allergy and Clinical Immunology suggests that diseases such as psoriasis and atopic dermatitis increase the risk of COVID-19 by approximately 50%. The authors of the study (Lam Tsoi and collaborators, University of Michigan) examined the medical records of 435,000 individuals, 1,115 of whom had been diagnosed with COVID-19.
In a recent publication in Nature Communications1 a team from Friedrich-Alexander University in Germany described their findings from a cross-sectional population cohort study on the prevalence of anti-SARS-CoV-2 immunoglobulin G (IgG) in patients with chronic immune-mediated inflammatory diseases (IMIDs) on cytokine-blocking treatments.
Recently, the Task Force (TF) of the National Psoriasis Foundation (NPF) released a revised version of its COVID-19 statement after an in-depth analysis of publicly available data with two currently approved anti-SARS-CoV-2 vaccines in the US, both mRNA-based.
Commentary provided on this international moderate-severe psoriasis case series, where biologics use was associated with lower risk of COVID-19-related hospitalization than non-biologic systemic therapies, however further investigation is warranted due to potential selection bias and unmeasured confounding.
